Establishment of a Prospective Clinical and Biological Database for Patients with Pancreatic Adenocarcinoma

What this Trial Is About

Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis, having an overall survival rate of less than 5% at five years across all stages. The number of cases and deaths from PA has been rising steadily for two decades, and without new treatments, it is expected to become one of the leading causes of cancer deaths by 2030. This research focuses on understanding the tumor and its microenvironment, which includes various cells and extracellular components that influence tumor growth and resistance to treatments. New technologies like CyTOF are being used to analyze the cellular makeup of tumors and explore ways to disrupt harmful interactions between tumor cells and their surroundings. The study involves collecting biological samples such as blood and tissue from patients with pancreatic adenocarcinoma before and during their treatments, including surgery and chemotherapy. These samples will be used to develop and characterize patient-derived tumor models and analyze the tumors' molecular and genetic features. This approach aims to support personalized medicine strategies and improve understanding of drug resistance and tumor biology. The study is monocentric and prospective, building a clinical and biological database over several years. Participants will provide consent and have their clinical data recorded alongside biological samples collected throughout their treatment journey. Researchers will monitor patient participation rates and gather detailed information to evaluate tumor characteristics and treatment responses. The study will continue for up to eight years, allowing long-term observation and data collection to support future translational research and development of new therapies.

Prospective Monocentric Clinical-biological Database